623564-40-9
Chemical Structure
BLI-489
- CAS No.: 623564-40-9
- Formula:C13H10N3NaO4S
- Molecular Weight:327.29
IUPAC Name: sodium (R,Z)-6-((5,6-dihydro-8H-imidazo[2,1-c][1,4]oxazin-2-yl)methylene)-7-oxo-4-thia-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylate
InChIKey: RFSWVJXWZXQOSW-ZDFSRXSCSA-M
SMILES: O=C(C1=CS[C@@](/C2=C/C3=CN4C(COCC4)=N3)([H])N1C2=O)O[Na]
Biological Activity: BLI-489 is a Beta-lactamase inhibitor. BLI-489 is an antibacterial adjuvant that significantly enhances the antibacterial efficacy of β-lactam antibiotics. BLI-489 blocks the hydrolytic activity of the enzyme by forming a stable intermediate in serine Beta-lactamase, or by coordinating with the binuclear Zn2+ through an oxygen atom in metallo-Beta-lactamase. BLI-489 can be used for research on bacterial infections[1][2][3][4].
| Cat. No. | Nom du produit | Pureté | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
BLI-489 | 95.77% | BLI-489 is a Beta-lactamase inhibitor. BLI-489 is an antibacterial adjuvant that significantly enhances the antibacterial efficacy of β-lactam antibiotics. BLI-489 blocks the hydrolytic activity of the enzyme by forming a stable intermediate in serine Beta-lactamase, or by coordinating with the binuclear Zn2+ through an oxygen atom in metallo-Beta-lactamase. BLI-489 can be used for research on bacterial infections. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
BLI-489 (Standard) | ≥98% | BLI-489 Standard is the analytical standard of BLI-489 (HY-108062). This product is intended for research and analytical applications. BLI-489 is a Beta-lactamase inhibitor. BLI-489 is an antibacterial adjuvant that significantly enhances the antibacterial efficacy of β-lactam antibiotics. BLI-489 blocks the hydrolytic activity of the enzyme by forming a stable intermediate in serine Beta-lactamase, or by coordinating with the binuclear Zn2+ through an oxygen atom in metallo-Beta-lactamase. BLI-489 can be used for research on bacterial infections. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Petersen PJ, et al. Establishment of in vitro susceptibility testing methodologies and comparative activities of piperacillin in combination with the penem {beta}-lactamase inhibitor BLI-489. Antimicrobial agents and chemotherapy. 2009 Feb;53(2):370-84. [Content Brief]
- [2]. Wang YC, et al. In vitro and in vivo activities of imipenem combined with BLI-489 against class D β-lactamase-producing Acinetobacter baumannii. The Journal of antimicrobial chemotherapy. 2021 Jan 19;76(2):451-459. [Content Brief]
- [3]. Petersen PJ, et al. Efficacy of piperacillin combined with the Penem beta-lactamase inhibitor BLI-489 in murine models of systemic infection. Antimicrobial agents and chemotherapy. 2009 Apr;53(4):1698-700. [Content Brief]
- [4]. Damaceno NdS, et al. Synergistic effects of ceftriaxone combined with BLI-489 against NDM-producing Klebsiella pneumoniae. Microbiol Spectr. 2026 Apr 7;14(4):e0157525.
